Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Tesamorelin is a synthetic GHRH analog that stimulates pituitary GH release, reducing visceral (abdominal) adipose tissue through enhanced lipolysis. Clinical trials in HIV-associated lipodystrophy show 15–20% visceral fat reduction, and separate studies show cognitive benefits in older adults.
FDA-approved Egrifta (tesamorelin) for HIV lipodystrophy costs $5,000+/month. Compounded tesamorelin provides the same peptide at dramatically lower cost for patients prescribed it for off-label metabolic and cognitive indications.
Compare up to 7,500 pharmacies across the USA.
Tesamorelin is a synthetic analog of GHRH (growth hormone-releasing hormone) with a trans-3-hexenoic acid modification that extends its half-life. It is the only GHRH analog with FDA approval — for HIV-associated lipodystrophy — giving it the strongest clinical evidence base of any GH peptide.
Beyond HIV lipodystrophy, tesamorelin has compelling evidence for visceral fat reduction in metabolic syndrome and for cognitive function improvement in older adults — reducing the risk of mild cognitive impairment progression.
Visceral fat reduction, metabolic syndrome, HIV lipodystrophy, cognitive decline prevention, body composition optimization
Standard: 1–2mg SubQ daily
Labs: IGF-1 at baseline and 3 months to assess response and adjust dosing
Injection site reactions (most common), water retention, joint aching, glucose elevation (monitor fasting glucose). Generally well tolerated at therapeutic doses.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
